When a Uniquely Effective Drug is Teratogenic: The Case of Isotretinoin

Publisher Website
Google Scholar
Abstract
To the Editor: Just one week after a Journal editorial on the disclosure of investigators' financial ties (April 6 issue),1 there was a Sounding Board article on isotretinoin (Accutane) by Dr. Robert Stern (April 13 issue),2 in which no disclosure was made of his substantial association with Hoffmann–LaRoche (Roche), the manufacturer of isotretinoin. At the April 26, 1988, meeting of the Dermatologic Drugs Advisory Committee of the Food and Drug Administration, Dr. Stern disqualified himself from voting on Accutane because of what he described as "my continuing support for a research project from Hoffmann–LaRoche company and other consulting work I . . .

This publication has 10 references indexed in Scilit: